12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MammaPrint diagnostic data

Agendia reported five-year follow-up data from the prospective Dutch RASTER observational study in 427 women with primary breast carcinoma showing that use of Agendia's MammaPrint in addition to standard guidelines used to select patients for adjuvant systemic therapy could lead to a 20% reduction in the use of adjuvant chemotherapy vs. standard guidelines alone. Specifically, MammaPrint classified 51% and 49% of patients as "low risk" and "high risk" for breast cancer recurrence, respectively, vs. 31% and 69% as determined by Adjuvant! Online,...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >